KAPE-TECHNOLOGIES
1.8.2024 14:12:36 CEST | Business Wire | Press release
Kape Technologies today announced the appointment of Ankit Khemka as Chief Marketing Officer (CMO), strengthening the group’s senior leadership team and bolstering the company’s commitment to building a safer, freer internet with its industry-leading privacy and security technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801380656/en/
Ankit Khemka (Photo: Business Wire)
Khemka is a seasoned professional with a diverse background in Brand Building, Growth Marketing and strategic business development. Most recently, Khemka served as Global General Manager and Head of Marketing at Revolut. Prior to this, he worked at HelloFresh and Rocket Internet Group, building and scaling businesses across the US, India, Europe, and Latin America.
Khemka will leverage his global experience in fast-growing companies to accelerate the growth of Kape’s privacy products, including its flagship privacy brand, ExpressVPN. In his new position, he will lead marketing activities, reinforcing the company’s strong customer-centric culture and driving initiatives to maximize growth opportunities.
"I am delighted to appoint Ankit to propel the next chapter of growth and innovation for Kape Technologies and its brands. The leadership team and I share a strong vision for the future of Kape. I am confident that Ankit’s marketing leadership and vision will be invaluable to our team as we continue to grow and innovate,” said Charles Butler, CEO, Kape Technologies. “Together we remain laser-focused on our mission to establish Kape as the world’s leading privacy-first digital security provider, empowering customers to take control of their privacy and security.”
Ankit Khemka, CMO, Kape Technologies said, “Kape Technologies’ flagship brand, ExpressVPN, has been at the forefront of the VPN industry for over a decade, thanks to its dedication to technical excellence, innovation, and customer-centricity. I am excited to build upon this solid foundation and unlock the immense potential for further growth. With our shared vision and the combined strength of our team, I am confident that we will take the company to new heights, setting the standard for the privacy and security industry.”
About Kape Technologies
Kape Technologies is a leading privacy-first digital security software provider to consumers. Through its range of privacy and security products, Kape focuses on protecting consumers and their personal data as they go about their daily digital lives.
With over 7 million paying subscribers, Kape has a proven track record of growth, underpinned by a strong business model and expert digital marketing. Kape's highly scalable SaaS-based operating structure is geared toward capitalizing on the vast global consumer digital privacy market.
About ExpressVPN
Since 2009, ExpressVPN has empowered millions of users to take control of their internet experience. The company’s award-winning consumer VPN service is backed by its open-source VPN protocol Lightway, delivering user privacy in just a few clicks. ExpressVPN’s Keys password manager and Aircove router make digital privacy and security easy and accessible for all. ExpressVPN’s products have been extensively vetted by third-party experts, including PwC, Cure53, KPMG, and others.
ExpressVPN has been part of Kape Technologies since 2021. To learn more about ExpressVPN’s industry-leading privacy and security solutions, visit www.expressvpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801380656/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom